Efficacy of Antibodies and Antiviral Drugs against Covid-19 Omicron Variant

Emi Takashita; Noriko Kinoshita; Seiya Yamayoshi; Yuko Sakai-Tagawa; Seiichiro Fujisaki; Mutsumi Ito; Kiyoko Iwatsuki-Horimoto; Shiho Chiba; Peter Halfmann; Hiroyuki Nagai; Makoto Saito; Eisuke Adachi; David Sullivan; Andrew Pekosz; Shinji Watanabe; Kenji Maeda; Masaki Imai; Hiroshi Yotsuyanagi; Hiroaki Mitsuya; Norio Ohmagari; Makoto Takeda; Hideki Hasegawa; Yoshihiro Kawaoka

doi:10.1056/NEJMc2119407

Efficacy of Antibodies and Antiviral Drugs against Covid-19 Omicron Variant

Emi Takashita, Noriko Kinoshita, Seiya Yamayoshi, Yuko Sakai-Tagawa, Seiichiro Fujisaki, Mutsumi Ito, Kiyoko Iwatsuki-Horimoto, Shiho Chiba, Peter Halfmann, Hiroyuki Nagai, Makoto Saito, Eisuke Adachi, David Sullivan, Andrew Pekosz, Shinji Watanabe, Kenji Maeda, Masaki Imai, Hiroshi Yotsuyanagi, Hiroaki Mitsuya, Norio OhmagariMakoto Takeda, Hideki Hasegawa, Yoshihiro Kawaoka

Bloomberg School of Public Health

Research output: Contribution to journal › Letter › peer-review

Original language	English (US)
Pages (from-to)	995-998
Number of pages	4
Journal	New England Journal of Medicine
Volume	386
Issue number	10
DOIs	https://doi.org/10.1056/NEJMc2119407
State	Published - Mar 10 2022

ASJC Scopus subject areas

General Medicine

Access to Document

10.1056/NEJMc2119407

Cite this

Takashita, E., Kinoshita, N., Yamayoshi, S., Sakai-Tagawa, Y., Fujisaki, S., Ito, M., Iwatsuki-Horimoto, K., Chiba, S., Halfmann, P., Nagai, H., Saito, M., Adachi, E., Sullivan, D., Pekosz, A., Watanabe, S., Maeda, K., Imai, M., Yotsuyanagi, H., Mitsuya, H., ... Kawaoka, Y. (2022). Efficacy of Antibodies and Antiviral Drugs against Covid-19 Omicron Variant. New England Journal of Medicine, 386(10), 995-998. https://doi.org/10.1056/NEJMc2119407

Takashita, E, Kinoshita, N, Yamayoshi, S, Sakai-Tagawa, Y, Fujisaki, S, Ito, M, Iwatsuki-Horimoto, K, Chiba, S, Halfmann, P, Nagai, H, Saito, M, Adachi, E, Sullivan, D , Pekosz, A, Watanabe, S, Maeda, K, Imai, M, Yotsuyanagi, H, Mitsuya, H, Ohmagari, N, Takeda, M, Hasegawa, H & Kawaoka, Y 2022, 'Efficacy of Antibodies and Antiviral Drugs against Covid-19 Omicron Variant', New England Journal of Medicine, vol. 386, no. 10, pp. 995-998. https://doi.org/10.1056/NEJMc2119407

@article{069f18641f57455d9835f148b93922de,

title = "Efficacy of Antibodies and Antiviral Drugs against Covid-19 Omicron Variant",

author = "Emi Takashita and Noriko Kinoshita and Seiya Yamayoshi and Yuko Sakai-Tagawa and Seiichiro Fujisaki and Mutsumi Ito and Kiyoko Iwatsuki-Horimoto and Shiho Chiba and Peter Halfmann and Hiroyuki Nagai and Makoto Saito and Eisuke Adachi and David Sullivan and Andrew Pekosz and Shinji Watanabe and Kenji Maeda and Masaki Imai and Hiroshi Yotsuyanagi and Hiroaki Mitsuya and Norio Ohmagari and Makoto Takeda and Hideki Hasegawa and Yoshihiro Kawaoka",

note = "Funding Information: by a Research Program on Emerging and Reemerging Infectious Diseases (JP20fk0108412 and JP21fk0108615, to Dr. Kawaoka; JP21fk0108104, to Dr. Watanabe), a Project Promoting Support for Drug Discovery (JP20nk0101632, to Dr. Kawaoka), the Japan Program for Infectious Diseases Research and Infrastructure (JP21wm0125002, to Dr. Kawaoka) from the Japan Agency for Medical Research and Development, a Grant-in-Aid for Emerging and Reemerging Infectious Diseases from the Ministry of Health, Labor, and Welfare, Japan (20HA2007, to Dr. Hasegawa), and by the U.S. Department of Defense Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense, in collaboration with the Defense Health Agency (contract number W911QY2090012, to Dr. Sullivan). Funding Information: Supported by grants from the Center for Research on Influenza Pathogenesis (HHSN272201400008C, to Dr. Kawaoka) and from the Center for Research on Influenza Pathogenesis and Transmission (75N93021C00014, to Dr. Kawaoka), funded by the National Institutes of Allergy and Infectious Diseases, and",

year = "2022",

month = mar,

day = "10",

doi = "10.1056/NEJMc2119407",

language = "English (US)",

volume = "386",

pages = "995--998",

journal = "New England Journal of Medicine",

issn = "0028-4793",

publisher = "Massachussetts Medical Society",

number = "10",

}

TY - JOUR

T1 - Efficacy of Antibodies and Antiviral Drugs against Covid-19 Omicron Variant

AU - Takashita, Emi

AU - Kinoshita, Noriko

AU - Yamayoshi, Seiya

AU - Sakai-Tagawa, Yuko

AU - Fujisaki, Seiichiro

AU - Ito, Mutsumi

AU - Iwatsuki-Horimoto, Kiyoko

AU - Chiba, Shiho

AU - Halfmann, Peter

AU - Nagai, Hiroyuki

AU - Saito, Makoto

AU - Adachi, Eisuke

AU - Sullivan, David

AU - Pekosz, Andrew

AU - Watanabe, Shinji

AU - Maeda, Kenji

AU - Imai, Masaki

AU - Yotsuyanagi, Hiroshi

AU - Mitsuya, Hiroaki

AU - Ohmagari, Norio

AU - Takeda, Makoto

AU - Hasegawa, Hideki

AU - Kawaoka, Yoshihiro

N1 - Funding Information: by a Research Program on Emerging and Reemerging Infectious Diseases (JP20fk0108412 and JP21fk0108615, to Dr. Kawaoka; JP21fk0108104, to Dr. Watanabe), a Project Promoting Support for Drug Discovery (JP20nk0101632, to Dr. Kawaoka), the Japan Program for Infectious Diseases Research and Infrastructure (JP21wm0125002, to Dr. Kawaoka) from the Japan Agency for Medical Research and Development, a Grant-in-Aid for Emerging and Reemerging Infectious Diseases from the Ministry of Health, Labor, and Welfare, Japan (20HA2007, to Dr. Hasegawa), and by the U.S. Department of Defense Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense, in collaboration with the Defense Health Agency (contract number W911QY2090012, to Dr. Sullivan). Funding Information: Supported by grants from the Center for Research on Influenza Pathogenesis (HHSN272201400008C, to Dr. Kawaoka) and from the Center for Research on Influenza Pathogenesis and Transmission (75N93021C00014, to Dr. Kawaoka), funded by the National Institutes of Allergy and Infectious Diseases, and

PY - 2022/3/10

Y1 - 2022/3/10

UR - http://www.scopus.com/inward/record.url?scp=85124609059&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85124609059&partnerID=8YFLogxK

U2 - 10.1056/NEJMc2119407

DO - 10.1056/NEJMc2119407

M3 - Letter

C2 - 35081300

AN - SCOPUS:85124609059

SN - 0028-4793

VL - 386

SP - 995

EP - 998

JO - New England Journal of Medicine

JF - New England Journal of Medicine

IS - 10

ER -

Efficacy of Antibodies and Antiviral Drugs against Covid-19 Omicron Variant

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this